Innoviva Specialty的淋病抗生素将接受FDA审查

Innoviva Specialty Therapeutics, a unit of Innoviva (NASDAQ:INVA), said that the U.S. FDA has accepted to review the marketing application for its oral antibiotic, zoliflodacin, to treat gonorrhea in patients 12 years and older.

Entasis Therapeutics retains the commercial rights for zoliflodacin in North America, Europe, and Asia-Pacific, while Global Antibiotic Research & Development Partnership retains the right to commercialize the product in more than three-quarters of the world’s countries.

Zoliflodacin has already received the designation of Qualified Infectious Disease Product from the U.S. FDA.